glp-1 gip dual agonist Schematic illustration of monoagonists, agonists and triple Fair Allocation of GLP-1 and

Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y, et al

Weight Loss: Average weight loss in the LEAD trials was 2 kg to 3.24 kg, with the majority of the reduction noted in the first 4 months of therapy, but tending to be sustained throughout the remaining period of the studies

Still in clinical trials, this triple agonist has shown remarkable results in early studies

demonstrated that although the combination therapy (metformin 1000 mg BID + liraglutide 1.2 mg/day) resulted in a greater weight loss than liraglutide alone, both groups showed an increase in SHBG and a decrease in free testosterone, with no differences between the two treatment arms, thus suggesting that the effect on the biochemical hyperandrogenism of liraglutide may be partially independent of the extent of weight loss [60]

Insurance covers GLP-1 medications, but coverage extent varies by your provider, location, and health circumstances

In addition to appetite control, GLP-1 injections can improve insulin sensitivity and help regulate blood sugar levels, which is particularly beneficial for people with obesity or those at risk of developing type 2 diabetes